Adverse Effects of New Cephalosporins
Authors: STEPHEN G. JENKINSON
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 March 1983Adverse Effects of New CephalosporinsSTEPHEN G. JENKINSON, M.D.STEPHEN G. JENKINSON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-3-415_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: In his review of the new beta-lactamase stable cephalosporins (1), Dr. Neu states that a number of bleeding problems in patients using these agents have been reported. He also states that a disulfiran-type reaction can occur in patients receiving a beta-lactamase stable cephalosporin up to 72 hours after stopping treatment. I can find no evidence in the literature of these reactions occurring with cefotaxime therapy and would like Dr. Neu to share his experiences with regard to these types of side effects with this widely used new beta-lactamase stable cephalosporin....Reference1. NEU H. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982;97:408-19. LinkGoogle Scholar1. KAMMER R. Moxalactam: clinical summary of efficacy and safety. Rev Infect Dis. 1982;4(Suppl):712-19. CrossrefGoogle Scholar2. REDDYBAILEY JR. Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics. N Zealand Med J. 1980;92:378-9. MedlineGoogle Scholar3. HOOPERHANEYSTONE CBA. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole. Lancet. 1980;1:39-40. CrossrefMedlineGoogle Scholar4. SRINIVASANFRANCKENEU SEH. Use of moxalactam in therapy of infections due to multiresistant bacteria. In: Program and Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology; 1980. (Abstract 365). Google Scholar5. ANDRASSAYKODERISCHRITZ KJE. Influence of cefotaxime (CTX), cefoperazone (CP) and lamoxactam (MOX) on blood coagulation and platelet function. In: Program and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology; 1980. (Abstract 523). Google Scholar6. WEITEKAMPABER MR. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983;249:69-71. CrossrefMedlineGoogle Scholar7. NEUPRINCE HA. Interaction between moxalactam and alcohol. Lancet. 1980;1:1422. CrossrefMedlineGoogle Scholar8. MCMAHON F. Disulfiram-like reaction to a cephalosporin. JAMA. 1980;243:2397. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: STEPHEN G. JENKINSON, M.D.Affiliations: Louisiana State University Medical Center Shreveport, LA 71130 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPrinciples of Anti-infective TherapyPrinciples of Anti-infective TherapyInhibitory effects of antibiotics on platelet aggregation in vitroLack of Effect of Cefixime on the Metabolism of Vitamin K 1Effects of aztreonam on fecal flora and on vitamin K metabolismOrigin of oncologic anesthetic techniquesPhase I Clinical Studies of 7432-S, a New Oral Cephalosporin: Safety and PharmacokineticsPhase I Clinical Studies of 7432-S: Effect of 7432-S on Platelet Aggregation and Blood CoagulationEffects of 1-S Replaced and/or Decarboxylated Latamoxef on Rabbit Platelet Aggregation In VitroEffect of latamoxef (moxalactam) and its related compounds on platelet aggregation in vitro structure activity relationshipsHematological Effects Associated with Beta-Lactam UseCephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?In vitro activity of BRL 36650, a new semisynthetic penicillinCefoperazone-Induced CoagulopathyThird generation cephalosporin antibiotics in surgical practiceLatamoxef versus Carbenicillin plus Gentamicin or Carbenicillin plus Mecillinam in Leukopenic, Febrile Patients with Solid TumorsEffects of Antibiotics on Fibrinolytic ActivityAntibiotic‐induced hypoprothrombinaemiaComparative toxicities of third-generation cephalosporinsDrugs affecting blood clotting and hemostasisMoxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patientsSevere Bleeding Diathesis Associated with Moxalactam AdministrationCephalosporin antibiotic agentsIn vitro activity of HR 810, a new cephalosporinMulticenter Clinical Trial of Cefoperazone Sodium in the United StatesIn vitro evaluation of U63196-E (AC-1370): Antimicrobial activity, β-lactamase stability, and β-lactamase inhibitionCeftizoxime: A Beta-Lactamase-Stable, Broad-Spectrum CephalosporinISCHAEMIC HEART DISEASE MORTALITYLATAMOXEF-ASSOCIATED HYPOPROTHROMBINAEMIAMoxalactam and HemorrhageSTEPHEN R. JONES, M.D., ROBERT C. KIMBROUGH III, M.D. 1 March 1983Volume 98, Issue 3Page: 415-416KeywordsHemorrhage ePublished: 1 December 2008 Issue Published: 1 March 1983 PDF downloadLoading ...